{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-23384406-linaclotide:v1","objectPathId":"pubmed-pmid-23384406-linaclotide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-23384406-linaclotide/","json":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-23384406-linaclotide-v1.json","markdown":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-23384406-linaclotide-v1.md"},"story":{"slug":"pubmed-pmid-23384406-linaclotide","version":1,"domain":"Literature metadata","dateInSource":"2026-01-28","sourceCheckedAt":"2026-07-30","publishedAt":"2026-08-13","peptideSlugs":["linaclotide"],"peptides":[{"slug":"linaclotide","url":"https://peptidescanner.com/peptides/linaclotide/"}]},"claims":[{"id":"headline","text":"An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials.","sourceIds":["pubmed-observation-pmid-23384406-2026-01-28-f13eb769169e"]},{"id":"summary","text":"PubMed lists PMID 23384406 in Neurogastroenterology and motility as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-02-06 (day precision). PeptideScanner associated the retained record with the identity slug linaclotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-23384406-2026-01-28-f13eb769169e"]},{"id":"paragraph-1","text":"PubMed lists PMID 23384406 in Neurogastroenterology and motility as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-02-06 (day precision). PeptideScanner associated the retained record with the identity slug linaclotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-23384406-2026-01-28-f13eb769169e"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-23384406-2026-01-28-f13eb769169e"]}],"sources":[{"id":"pubmed-observation-pmid-23384406-2026-01-28-f13eb769169e","name":"PubMed","sourceClass":"A","title":"An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials. · retained source version 1:2026-01-28:current:f13eb769169ecaff2e102ebff7f8baae47ad35356ae50f4223e8fdfd256c15b5","url":"https://pubmed.ncbi.nlm.nih.gov/23384406/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"c171732103bf7be3c6b513a84990232c7bf616ef76e74a44fb40383f811a904e","tierARecordSha256":"10ac805d097a1d47990468825942259404fabfe7f65d409b78ca74dc10375a4c"},"integrity":{"algorithm":"sha256","contentSha256":"be4ef46bae5e8c6e4d7236835d7782d08ecd6da068a3b0d19907f377bdd8fade"}}